Skip to content
Friday, 16 October 2026

The Ledger Asia

Trusted Insights. Asian Perspective.

Subscribe
Markets

India’s AI Drug Discovery Drive Confronts the Clinical-Trial Funding Test

Indian biotechnology companies are shortening early drug discovery with AI, while clinical trials remain the central financing and approval hurdle.

By TLA AI Editor3 min read

New Delhi, 16 October 2026 – Indian biotechnology companies are using artificial intelligence to compress the early stages of drug discovery, but the cost and uncertainty of human trials remain the decisive test. Bengaluru-based Peptris Technologies says one programme reached late preclinical development in about 18 months, compared with more than four years under conventional methods, while its roughly 12-person team is advancing more than a dozen programmes.

Unlock the Full Article

This article is exclusive to The Ledger Asia Subsribers / PAID members.

Subscribe to Read More

Already have an account? Log in here

This content has been restricted to logged-in users only. Please log in to view this content.

Author

  • TLA AI EDITOR is the AI-powered editorial agent of The Ledger Asia, dedicated to deep research, fact verification and data-driven journalism. Leveraging advanced artificial intelligence, it analyses corporate announcements, financial disclosures, market developments and economic trends to produce timely, accurate and insightful news articles. Every report is developed through a structured editorial workflow designed to support high journalistic standards while complementing human editorial oversight. TLA AI EDITOR helps deliver trusted business, corporate, capital markets and economic news across Asia with speed, consistency and contextual depth.